Page 7 of Global Markets Direct Reports at RnR Market Research

Global Markets Direct Market Research Reports

Title	published	price
6364633 Osteonecrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Osteonecrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteonecrosis - Drugs In ...	31-Oct-2022	$2000
6364634 Pigmented Villonodular Synovitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Pigmented Villonodular Synovitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pigmen ...	31-Oct-2022	$2000
6364635 Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Drugs ...	31-Oct-2022	$2000
6364636 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare ...	31-Oct-2022	$2000
6364637 Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chro ...	31-Oct-2022	$2500
6364638 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare di ...	31-Oct-2022	$2000
6364639 Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lympho ...	31-Oct-2022	$2000
6364640 Chondrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Chondrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chondrosarcoma - Drugs I ...	31-Oct-2022	$2000
6364641 Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Drugs In ...	31-Oct-2022	$2000
6364642 Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astro ...	31-Oct-2022	$2000
6364643 Anaplastic Oligoastrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Anaplastic Oligoastrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic ...	31-Oct-2022	$2000
6364644 Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Drugs In Deve ...	31-Oct-2022	$2000
6364645 Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Drugs I ...	31-Oct-2022	$2000
6364646 Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Drugs In ...	31-Oct-2022	$2500
6364647 Gallbladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Gallbladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - ...	31-Oct-2022	$2000
6364648 Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Drugs ...	31-Oct-2022	$2500
6364649 Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - ...	31-Oct-2022	$2500
6364650 Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Drugs I ...	31-Oct-2022	$2000
6364651 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) p ...	31-Oct-2022	$3500
6364652 Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update By Global Markets Direct Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - ...	31-Oct-2022	$3500
«prev 1 \| 2 \| ... 5 \| 6 \| 7 \| 8 \| 9 \| .. 658 \| 659 next »

+ 1 888 391 5441
[email protected]

On the Web